Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: Relationship to elevated TPA antigen in patients with high PAI-1 activity levels

Circulation

Volumn 96, Issue 3, 1997, Pages 761-768

  Chandler, W L ^a   Alessi, M C ^b   Aillaud, M F ^b   Henderson, P ^a   Vague, P ^c   Juhan Vague, I ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INSERM   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Hepatic clearance; Plasma; Plasminogen activators

Indexed keywords

ALTEPLASE; ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD VOLUME; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HEART OUTPUT; HUMAN; HUMAN EXPERIMENT; LIVER CLEARANCE; MALE; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL;

EID: 0030803068     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.3.761     Document Type: Article

References (52)

1. Chandler WL, Levy WC, Stratton JR. The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation. 1995;92:2984-2994.
2. Chandler WL, Levy WC, Veith RC, Stratton JR. A kinetic model of the circulatory regulation of tissue plasminogen activator during exercise, epinephrine infusion, and endurance training. Blood. 1993;81:3293-3302.
3. Chandler WL. A kinetic model of the circulatory regulation of tissue plasminogen activator. Thromb Haemost. 1991;66:321-322.
4. Meade TW, Ruddock V, Stirling Y, Chakrabarti T, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
5. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation. 1996;94:2057-2063.
6. Hamsten A, Walldius G, Szamosi A, Blomback M, De Faire U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
7. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991;12:157-161.
8. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. Circulation. 1993;88: 2030-2034.
9. Thompson S, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction and death. N Engl J Med. 1995;332:635-641.
10. Ridker PM, Vaughan DE, Stampfer MJ, Manson JB, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
11. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serradimigni A. Plasma plasminogen activator inhibitor-1 in angina pectoris: influence of plasma insulin and acute-phase response. Arteriosclerosis. 1989;9:362-367.
12. Nicoloso G, Hauert J, Kruithof EKO, Melle GV, Bachmann F. Fibrinolysis in normal subjects: comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemost. 1988;59:299-303.
13. Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood. 1990; 76:930-937.
14. Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris: relation to gender, age and acute-phase reaction. Thromb Haemost. 1995;73:561-567.
15. Rijken DC, Juhan-Vague I, Collen D. Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay. J Lab Clin Med. 1983;101:285-294.
16. Alessi M, Juhan-Vague I, Declerck P, Collen D. Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. Thromb Res. 1991;62: 275-285.
17. Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation. 1988;77:660-669.
18. Booth NA, Walker E, Maughan R, Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood. 1987; 69:1600-1604.
19. Thorsen S, Philips M. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma: evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta. 1984;802: 111-118.
20. Rånby M, Nguyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes: biochemical and multicenter validation of a two site immunosorbent assay. Thromb Haemost. 1989;61:409-414.
21. Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood. 1984;64:907-913.
22. Alessi MC, Juhan-Vague I, Declerck PJ, Anfosso F, Gueunoun E, Collen D. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. Thromb Res. 1990; 60:509-516.
23. Rånby M, Sundell B, Nilsson TK. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost. 1989;62:917-922.
24. Huisman LGM, van Griensven JMT, Kluft C. On the role of Cl-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost. 1995;73:466-471.
25. Baughman RA. Pharmacokinetics of tissue plasminogen activator. In: Sobel BE, Collen D, Grossbard EB, eds. Tissue Plasminogen Activator in Thrombolytic Therapy. New York, NY: Marcel Dekker Inc; 1987:41-53.
26. Faulkner JA, Heigenhauser GF, Schork MA. The cardiac output-oxygen uptake relationship of men during graded bicycle ergometry. Med Sci Sports Exerc. 1976;9:148-154.
27. Mollison PL. Blood Transfusion In Clinical Medicine. Boston, Mass: Blackwell Scientific Publications Inc; 1983.
28. Keber D, Blinc A, Fettich J. Increase of tissue plasminogen activator in limbs during venous occlusion: a simple haemodynamic model. Thromb Haemost. 1990;64:433-437.
29. Witzleb E. Functions of the vascular system. In: Schmidt RF, Thews G, eds. Human Physiology. New York, NY: Springer-Verlag; 1983: 397-455.
30. van Hinsbergh VWM. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitor by endothelial cells. In: Kluft C, ed. Tissue-Type Plasminogen Activator (t-PA): Physiological and Clinical Aspects. Boca Raton, Fla: CRC Press; 1988:3-20.
31. Kooistra T, Bosma PJ, Tons HAM, van den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost. 1989;62:723-728.
32. Brommer EJ, Derkx FH, Schalekamp MA, Dooijewaard G, v d Klaauw MM. Renal and hepatic handling of endogenous tissue-type plasminogen activator and its inhibitor in man. Thromb Haemost. 1988;59:404-411.
33. Sprengers ED, Princen HMG, Kooistra T, Van Hinsbergh VWM. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med. 1985;105:751-758.
34. Wieczorek I, Ludlam CA, MacGregor I. Venous occlusion does not release von Willebrand factor, factor VIII, or PAI-1 from endothelial cells: the importance of consensus on the use of correction factors for haemoconcentration. Thromb Haemost. 1993;69:91-93.
35. van Hinsbergh VWM, Bauer KA, Kooistra T, Kluft C, Dooijewaard G, Sherman ML, Nieuwenhuizen W. Progress of fibrinolysis during tumor necrosis factor infusions in humans: concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood. 1990;76: 2284-2289.
36. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. J Clin Invest. 1996;97:37-46.
37. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda K, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996;2:800-803.
38. Alessi MC, Parrot G, Guenoun E, Scelles V, Vague P, Juhan-Vague I. Relation between plasma PAI activity and adipsin levels. Thromb Haemost. 1995;74:1200-1202. Letter.
39. Lundgren CH, Brown NA, Nordt TK, Sobel BH, Fujii S. Elaboration of type 1 plasminogen activator inhibitor from adipocytes: a potential pathogenic link between obesity and cardiovascular disease. Circulation. 1996;97:106-110.
40. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. In press.
41. Coleman PL, Patel PD, Cwikel BJ, Rafferty UM, Sznycer R, Gelehrter TC. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986;261:4352-4357.
42. Hekman CM, Loskutoff DJ. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys. 1988;262: 199-210.
43. de Boer A, Kluft C, Kroon JM, Kasper FJ, Schoemaker HC, Pruis J, Breimer DD, Soons PA, Emeis JJ, Cohen AF. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost. 1992;67:83-87.
44. Krause J. Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids. Fibrinolysis. 1988;2:133-142.
45. Tanswell P, Seifried E, Su PCAF, Feurer W, Rijken DC. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther. 1989;46:155-162.
46. Koster RW, Cohen AF, Kluft C, Kasper FJ, van der Wouw PA, Weatherley BC. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction. Clin Pharmacol Ther. 1991;50:267-277.
47. Wing LR, Hawksworth GM, Bennett B, Booth NA. Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system. J Lab Clin Med. 1991;117:109-114.
48. Emeis JJ, van den Hoogen CM, Jense D. Hepatic clearance of tissue-type plasminogen activator inhibitor in rats. Thromb Haemost. 1985;54:661-664.
49. Camani C, Kruithof EKO. Clearance receptors for tissue-type plasminogen activator. Int J Hematol. 1994;60:97-109.
50. Strickland DK, Kounnas MZ, Williams SE, Argraves WS. LDL receptor-related protein (LRP): a multiligand receptor. Fibrinolysis. 1994;8(suppl 1):204-215.
51. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). J Biol Chem. 1994;269:21198-21203.
52. Bohm T, Geiger M, Binder BR. Isolation and characterization of tissue-type plasminogen activator-binding proteoglycans from human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 1996;16:665-672.